Q-omics provides the consensus-scored ANKRD7 profile across patient tissues and cancer cell-line models. ANKRD7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ANKRD7 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ANKRD7 RNA expression shows 16,721 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LUAD, and UVM as cancer lineages where ANKRD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD7 survival associations across molecular data types. ANKRD7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD7 RNA expression–survival associations across cancer types. High ANKRD7 expression shows unfavorable associations in KICH, READ, BLCA, CESC and THCA, but favorable associations in ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ANKRD7 RNA expression.
This table summarizes ANKRD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD7 shows lower tumor expression in KIRC, STAD, THCA and COAD and higher tumor expression in LUAD and LUSC. The LUAD box plot shows higher ANKRD7 RNA expression in tumor versus normal tissue (log2 FC = +0.788, t-test p < 0.001).
This table shows molecular features associated with ANKRD7 in patient tissues and cancer cell lines. In patient samples, ANKRD7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and STOMACH.
